Clinical Trial Detail

NCT ID NCT03488251
Title PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Molecular Templates, Inc.

diffuse large B-cell lymphoma

B-cell lymphoma


Gemcitabine + MT-3724 + Oxaliplatin

Age Groups: senior adult

No variant requirements are available.